ReviewEJNMMI reports2026
Future scenarios of radioligand therapy in pheochromocytomas and paragangliomas.
Review in EJNMMI reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPheochromocytomas and paragangliomas (PPGL) are rare and heterogeneous neuroendocrine tumors for which therapeutic options remain limited, particularly in the metastatic or progressive setting. Radioligand therapy (RLT) has emerged as a promising strategy, leveraging tumor-specific molecular targets to deliver cytotoxic radiation.
objectiveThis review provides a structured and updated overview of RLT in PPGL, critically comparing the two main therapeutic radiopharmaceuticals-[
methodsA comprehensive literature search was conducted across PubMed, Scopus, and Web of Science (updated to August 2024), focusing on studies evaluating RLT in PPGL. Due to heterogeneity in study design, protocols, and outcome measures, a metaanalysis was not feasible.
resultsEvidence derives predominantly from small retrospective studies and a limited number of prospective cohorts. Both [
conclusionsRLT represents a valuable therapeutic option for patients with progressive or symptomatic PPGL. Advances in molecular imaging, alphaemitter therapies, and personalized dosimetry are expected to further refine treatment selection and improve outcomes. Larger prospective studies are needed to define optimal sequencing and integration into clinical practice.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.